Skip to main content

Published locations for Tofacitinib postmarketing trial data shed light on JAK inhibitor risks

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Tofacitinib postmarketing trial data shed light on JAK inhibitor risks

User login

  • Reset your password
  • /content/tofacitinib-postmarketing-trial-data-shed-light-jak-inhibitor-risks
  • /edermatologynews/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed-light
  • /familypracticenews/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed
  • /fedprac/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed-light-jak
  • /internalmedicinenews/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed
  • /rheumatologynews/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed-light
  • /ecardiologynews/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed-light
  • /cardiology/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed-light-jak
  • /rheumatology/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed-light-jak
  • /internalmedicine/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed-light
  • /dermatology/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed-light-jak
  • /familymedicine/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data-shed-light
  • /psoriatic-arthritis-icymi/article/248800/rheumatoid-arthritis/tofacitinib-postmarketing-trial-data